# Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

> **NCT00360854** · PHASE1 · UNKNOWN · sponsor: **Children's Cancer and Leukaemia Group** · enrollment: 48 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** erlotinib hydrochloride
- **GENETIC:** mutation analysis
- **GENETIC:** polymorphism analysis
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00360854
- **Lead sponsor:** Children's Cancer and Leukaemia Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00360854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00360854, "Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00360854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*